138 related articles for article (PubMed ID: 33824184)
1. Pembrolizumab-Associated CD8
Baldauf MC; Kapauer M; Joerger M; Flatz L; Rodriguez R; Frank S; Felbecker A; Hartmann-Fussenegger S; Hundsberger T
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33824184
[No Abstract] [Full Text] [Related]
2. Vasculitic neuropathy induced by pembrolizumab.
Aya F; Ruiz-Esquide V; Viladot M; Font C; Prieto-González S; Prat A; Arance A
Ann Oncol; 2017 Feb; 28(2):433-434. PubMed ID: 27864214
[No Abstract] [Full Text] [Related]
3. Drug-associated vasculitis occurring after treatment with pembrolizumab.
Tolaymat OA; Pinkston O; Wang B; Schenk WB; Joseph RW; Mergo PJ; Berianu F
Rheumatology (Oxford); 2019 Aug; 58(8):1501-1503. PubMed ID: 30892627
[No Abstract] [Full Text] [Related]
4. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Alley EW; Lopez J; Santoro A; Morosky A; Saraf S; Piperdi B; van Brummelen E
Lancet Oncol; 2017 May; 18(5):623-630. PubMed ID: 28291584
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
Metaxas Y; Rivalland G; Mauti LA; Klingbiel D; Kao S; Schmid S; Nowak AK; Gautschi O; Bartnick T; Hughes BG; Bouchaab H; Rothschild SI; Pavlakis N; Wolleb S; Petrausch U; O'Byrne K; Froesch P; Löffler-Baumann M; Pratsch-Peter S; Russell P; Mingrone W; Savic S; Thapa B; Früh M; Pless M; von Moos R; John T
J Thorac Oncol; 2018 Nov; 13(11):1784-1791. PubMed ID: 30142389
[TBL] [Abstract][Full Text] [Related]
6. Vasculitic mononeuritis multiplex induced by valacyclovir.
Pary LF; Henszel A; Kelkar P
Neurology; 2004 May; 62(10):1906-7. PubMed ID: 15159513
[No Abstract] [Full Text] [Related]
7. Peripheral Vasculitic Neuropathy Associated With Minocycline Use.
Kang MK; Gupta RK; Srinivasan J
J Clin Neuromuscul Dis; 2018 Mar; 19(3):138-141. PubMed ID: 29465615
[TBL] [Abstract][Full Text] [Related]
8. IgA nephropathy after pembrolizumab therapy for mesothelioma.
Wang R; Das T; Takou A
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257374
[TBL] [Abstract][Full Text] [Related]
9. A Potential Immune Therapy for Mesothelioma.
Cancer Discov; 2015 Jul; 5(7):OF14. PubMed ID: 25956959
[No Abstract] [Full Text] [Related]
10. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
11. Hepatobiliary and Pancreatic: Biliary injury related to checkpoint inhibitor "pembrolizumab".
Kida A; Matsuda K; Matsuda M; Sakai A
J Gastroenterol Hepatol; 2019 Sep; 34(9):1478. PubMed ID: 31197882
[No Abstract] [Full Text] [Related]
12. Anti-TNF-α drug-induced lupus presenting with cutaneous vasculitis and mononeuritis multiplex.
Jeries H; Hassan F; Khoury W; Samih B; Naffaa ME
Int J Rheum Dis; 2024 Jun; 27(6):e15212. PubMed ID: 38831524
[No Abstract] [Full Text] [Related]
13. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
[TBL] [Abstract][Full Text] [Related]
14. Novel therapies for malignant pleural mesothelioma.
Scherpereel A; Wallyn F; Albelda SM; Munck C
Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
[TBL] [Abstract][Full Text] [Related]
15. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.
Cornelissen R; Lievense LA; Robertus JL; Hendriks RW; Hoogsteden HC; Hegmans JP; Aerts JG
Lung Cancer; 2015 Jun; 88(3):332-7. PubMed ID: 25843042
[TBL] [Abstract][Full Text] [Related]
18. [Effect of Pembrolizumab on T Lymphocyte Subsets in Patients with Advanced
Non-small Cell Lung Cancer and Its Therapeutic Effect].
Wang Y; Wang Y; Jiang M; Zhao Y; Zhang X
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):182-187. PubMed ID: 33819968
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma.
Bickel A; Koneth I; Enzler-Tschudy A; Neuweiler J; Flatz L; Früh M
BMC Cancer; 2016 Aug; 16():656. PubMed ID: 27543082
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.
Yap TA; Nakagawa K; Fujimoto N; Kuribayashi K; Guren TK; Calabrò L; Shapira-Frommer R; Gao B; Kao S; Matos I; Planchard D; Chatterjee A; Jin F; Norwood K; Kindler HL
Lancet Respir Med; 2021 Jun; 9(6):613-621. PubMed ID: 33836153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
